Long-Term Suppression of Viral Replication in Chronic Hepatitis B: Outcomes and Future Directions

참고문헌 (10)

1. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
2. Chen JD, "Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death", Gastroenterology, 138, pp.1747~1754 (2010)
3. Suk KT, "Revision and update on clinical practice guideline for liver cirrhosis", Korean J Hepatol, 18, pp.1~21 (2012)
4. Chen CF, "Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma", Gastroenterology, 141, pp.1240~1248 (2011)
5. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
6. Niro GA, "Long-term outcome of hepatitis B virus-related chronic hepatitis under protracted nucleos(t)ide analogues", J Viral Hepat, 20, pp.502~509 (2013)
7. Park YH, "Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea", J Gastroenterol Hepatol, 29, pp.1005~1011 (2014)
8. Cho JY, "Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease", Gut, 63, pp.1943~1950 (2014)
9. Idilman R, "Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting", J Viral Hepat, 22, pp.504~510 (2015)
10. 문진창, "Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy", Gut and Liver, 9(3), pp.395~404 (2015), 거트앤리버 발행위원회

관련 논문AI추천